Revolutionary cancer diagnosis: ISOPRACE® now available in Germany!

Revolutionary cancer diagnosis: ISOPRACE® now available in Germany!

Laimgrubengasse 10, 1060 Wien, Österreich - Revolution in cancer diagnosis! Isotopia has announced the introduction of ISOPRACE® in Germany today, and DSD Pharma will act as an exclusive sales partner. This groundbreaking partnership promises a quick and reliable delivery of the innovative radiopharmaceutical product to hospitals, clinics and diagnostic centers across the country, such as ots . ISOPRACE® supports the imaging diagnosis in prostate cancer and plays a decisive role in the treatment of this widespread disease, which results in over 70,000 new diagnoses in Germany annually.

So what is isoprace®? This state-of-the-art multidosis kit enables the quick preparation of a special Gozetotide solution for intravenous injection, perfectly tailored to the needs of positron emission tomography (PET) for prostate cancer. After the successful marking with Gallium (68GA), isoprace® is ready to be used in critical clinical scenarios. Tzachi Levy, Managing Director of Isotopia's aseptic facility, was pleased with the cooperation with DSD Pharma and emphasized the importance of the German market for the company. According to Dr. Susanne Dorudi from DSD Pharma will offer ISOPRACE® German doctors a new imaging solution that contributes significantly to increasing diagnostic and treatment results. This groundbreaking solution will not only be available in Germany, but is already approved in the Netherlands and will soon be available in over 10 EU countries, such as isotopia global supplemented.

summarized, the market launch of ISOPRACE® represents significant progress in radiopharmaceutical diagnostics that could revolutionize the cancer diagnosis. With a robust supply chain and a proven compliance standard, Isotopia does everything possible to ensure that access to this innovative treatment method is sustainable and significantly improve the quality of life of patients with prostate cancer.